COLORECTAL CANCER (MSI-H)

Clinical trials for COLORECTAL CANCER (MSI-H) explained in plain language.

Never miss a new study

Get alerted when new COLORECTAL CANCER (MSI-H) trials appear

Sign up with your email to follow new studies for COLORECTAL CANCER (MSI-H), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet recruiting 2 Not yet finished but already full! 1 Completed 2

Low-Dose immunotherapy shows promise against tough colorectal cancer

Disease control Ongoing

This study tests a low-dose immunotherapy drug (nivolumab or pembrolizumab) in 30 people with a specific type of advanced colorectal cancer (MSI/dMMR). The goal is to see if the treatment can shrink or eliminate the tumor before surgery. Participants receive the drug for 6 months…

Matched conditions: COLORECTAL CANCER (MSI-H)

Phase: PHASE2 • Sponsor: Blokhin's Russian Cancer Research Center • Aim: Disease control

Last updated May 14, 2026 12:06 UTC

COLORECTAL CANCER (MSI-H)

Get alerted when new COLORECTAL CANCER (MSI-H) trials appear

Low-Dose immunotherapy shows promise against tough colorectal cancer